Proficio Capital Partners LLC Purchases New Holdings in Natera, Inc. $NTRA

Proficio Capital Partners LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 2,272 shares of the medical research company’s stock, valued at approximately $617,000.

Several other institutional investors also recently modified their holdings of NTRA. Integrated Wealth Concepts LLC increased its position in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC raised its stake in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its position in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera in the 2nd quarter valued at $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $325.17 on Thursday. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $343.18. The business has a fifty day moving average of $289.96 and a two-hundred day moving average of $236.14. The stock has a market cap of $46.87 billion, a PE ratio of -239.09 and a beta of 1.54.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.74) EPS. Analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NTRA shares. Guggenheim increased their price objective on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Piper Sandler raised their price target on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, UBS Group set a $260.00 price objective on Natera in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares in the company, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the transaction, the chief financial officer directly owned 51,637 shares in the company, valued at $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,348 shares of company stock valued at $15,870,496 over the last three months. 5.05% of the stock is owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.